DRX has spent the two weeks since its earnings miss in a quiet but telling recovery — shorts are bailing, borrow remains cheap, and a $157M contract win has given the backlog story something to point at.
The catalyst that set the week's tone landed on April 16. ADF Group reported Q4 EPS of $0.23, missing the $0.41 consensus by a wide margin, as U.S. tariffs weighed on profit and revenue. The stock fell nearly 15% on the day and shed another 11.6% over the following five sessions. That drop was sharp enough to flush out a wave of short sellers — and the data since has been unambiguous: those shorts have been unwinding, not rebuilding.
Short interest is too small to be the primary story here, but its direction is noteworthy. At just 0.26% of the free float — barely a rounding error — bears were never crowded into this name. What's more telling is the pace of the exit: SI fell over 51% in a single week, dropping from roughly 89,000 shares short in mid-April to 43,000 by April 28. That looks less like a strategic retreat and more like opportunistic shorts covering after collecting gains from the earnings drop. The borrow market reflects none of the stress you'd associate with a squeeze. Cost to borrow has eased to 2.42% — down 24% on the week — and availability against short interest is running at over 1,000%, which is extremely loose. There is no pressure in the lending market, and nothing to suggest a short squeeze narrative.
The one analyst firm active on the stock recently is Atrium Research, which cut its FY2027 EPS estimate following the earnings miss. That move — a downward EPS revision in the wake of a tariff-driven margin squeeze — is the correct read of the situation, but it's a single voice and the action is now 7-8 days old. The only formal price target in the system dates to January 2026 at C$13.00, which implies meaningful upside from the current C$9.63 close, but given the staleness of that figure and the post-earnings repricing, it should be treated as directional at best. The stock has clawed back about 6% from its post-earnings low and is up 5.7% on the month, even after absorbing the selloff.
What's keeping the bull case alive is the backlog. The same April news cycle that delivered the earnings miss also carried a $157.3M contract win in Quebec and the U.S. — a number that, for a company with a market cap around C$160M, represents substantial forward revenue visibility. Management's pitch has shifted squarely to backlog quality over near-term earnings delivery, and that framing gives longer-term holders a reason to stay patient through the tariff turbulence.
The ORTEX short score has drifted back down to 32.4 after briefly spiking above 40 in the immediate aftermath of the earnings release, when short positioning briefly intensified. That spike has fully unwound. The combined ORTEX score of 31.9 and the sector score sitting at the 50th percentile describe a stock that is fairly neutral in positioning terms — neither heavily bet against nor attracting conviction buying. Peer steel names had a mixed week: WS gained 5.5% while CMC added 2.1%, suggesting the broader steel sector had a better week than DRX's flat-to-down performance implies.
The next meaningful signal will come from whether the backlog converts — the gap between backlog growth and near-term margin delivery is the central tension worth tracking as tariff conditions evolve.
See the live data behind this article on ORTEX.
Open DRX on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
